Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Clinical trial NCT05301530 · COMPLETED

Trial details

NCT number: NCT05301530
Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Metastatic Breast Cancer Female Breast Cancer Recurrent

Start date: 2019-05-27
Primary completion: 2020-08-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.